SCHEMBL4190670

SCHEMBL4190670

COc1ccc(S(=O)(=O)N2CCN(S(=O)(=O)c3ccc4c(c3)OCCO4)CC2)cc1OC

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 15/20 0.81
USP2 O75604 2/20 0.81
GAA P10253 1/20 0.81
PKLR P30613 7/20 0.74
KDM4E B2RXH2 1/20 0.74
NPC1 O15118 1/20 0.74
RAB9A P51151 1/20 0.74
HTT P42858 2/20 0.69
GPBAR1 Q8TDU6 1/20 0.68
MEN1 O00255 2/20 0.67
KMT2A Q03164 2/20 0.67
MAPT P10636 1/20 0.67
L3MBTL1 Q9Y468 1/20 0.67
LMNA P02545 2/20 0.63
TSHR P16473 2/20 0.63
CYP2C19 P33261 1/20 0.63
ALDH1A1 P00352 1/20 0.63
NPSR1 Q6W5P4 1/20 0.63
GLA P06280 1/20 0.62
MAPK1 P28482 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4186845 0.96 PKM (0.76) PKMUSP2GAAPKLRKDM4E
SCHEMBL3830421 0.86 GPBAR1 (0.90) PKMUSP2GAAKDM4EHTT
SCHEMBL4184681 0.86 GPBAR1 (0.90) PKMUSP2GAAKDM4EHTT
SCHEMBL1722758 0.86 PKM (1.00) PKMPKLRKDM4ENPC1RAB9A
SCHEMBL29548980 0.85 PKM (1.00) PKMUSP2GAAPKLRKDM4E
SCHEMBL1710881 0.85 PKM (1.00) PKMUSP2GAAPKLRKDM4E
SCHEMBL14384465 0.84 GPBAR1 (0.64) PKMUSP2GAAPKLRKDM4E
SCHEMBL4180216 0.83 PKM (0.58) PKMUSP2GAAPKLRKDM4E
SCHEMBL1722416 0.82 PKM (1.00) PKMUSP2GAAPKLRKDM4E
SCHEMBL29483631 0.82 KDM4E (0.77) PKMUSP2KDM4EHTTGPBAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 US disclosed
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 US disclosed
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 US disclosed
EP-1976498-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2008-10-08 EP disclosed
WO-2007127505-A2 USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF DISORDERS OF THE METABOLISM AND THE NERVOUS SYSTEM SMITHKLINE BEECHAM CORPORATION (US) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069302-A1 CHEMICAL COMPOUNDS TBXA2R, PDE4D, PDE4A PKM 3148/4885USP2 3517/4885GAA 2192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.